Efficacy of acute inhalation of nitric oxide in patients with primary pulmonary hypertension using chronic use of continuous epoprostenol infusion

Circulation Journal

Volumn 69, Issue 3, 2005, Pages 335-338

  Saji, Kenya ^a   Sakuma, Masahito ^a   Suzuki, Jun ^a   Takahashi, Tohru ^a   Demachi, Jun ^a   Nawata, Jun ^a   Kitamukai, Osamu ^a   Onoue, Noriko ^a   Sugimura, Kouichiro ^a   Tada, Tomohiro ^a   Fukui, Shigefumi ^a   Kagaya, Yutaka ^a   Watanabe, Jun ^a   Shirato, Kunio ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Epoprostenol; Fractional pulse pressure; Nitric oxide; Pulmonary angiography; Pulmonary arterial hypertension

Indexed keywords

NITRIC OXIDE; PROSTACYCLIN;

ADULT; AORTA PRESSURE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ABUSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FEMALE; HEART OUTPUT; HEART RIGHT ATRIUM PRESSURE; HUMAN; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; LUNG VASCULAR RESISTANCE; MALE; MEAN ARTERIAL PRESSURE; PULMONARY HYPERTENSION; SYSTEMIC VASCULAR RESISTANCE;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANGIOGRAPHY; BLOOD PRESSURE; CARDIAC OUTPUT; DRUG THERAPY, COMBINATION; EPOPROSTENOL; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; NITRIC OXIDE; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATION;

EID: 20144362363     PISSN: 13469843     EISSN: None     Source Type: Journal    
DOI: 10.1253/circj.69.335     Document Type: Article

References (30)

1. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in bone morphogenic protein receptor-II gene. Am J Hum Genet 2000; 67: 737-744.
2. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA 3rd, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension: The International PPH Consortium. Nat Genet 2000; 26: 81-84.
3. Sugiyama S, Hirota H, Yoshida M, Takemura Y, Nakaoka Y, Oshima Y, et al. Novel insertional mutation in the bone morphogenetic protein receptor type II associated with sporadic primary pulmonary hypertension. Circ J 2004; 68: 592-594.
4. Takahashi T, Sakuma M, Ikeda J, Nawata J, Demachi J, Kitamukai O, et al. Effect and problems of continuous infusion of epoprostenol for patients with primary pulmonary hypertension. Intern Med 2002; 41: 784-788.
5. Ueno M, Miyauchi T, Sakai S, Yamauchi-Kohno R, Goto K, Yamaguchi I. A combination of oral endothelin-A receptor antagonist and oral prostacyclin analogue is superior to each drug alone in ameliorating pulmonary hypertension in rats. J Am Coll Cardiol 2002; 40: 175-181.
6. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Samidurai A, Pullamsetti S, Weissmann N, et al. Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension. Circ Res 2004; 94: 1101-1108.
7. Itoh T, Nagaya N, Fujii T, Iwase T, Nakanishi N, Hamada K, et al. A combination of oral sildenafil and beraprost ameliorates pulmonary hypertension in rats. Am J Respir Crit Care Med 2004; 169: 5-6.
8. Nakayama Y, Nakanishi N, Sugimachi M, Takaki H, Kyotani S, Satoh T, et al. Characteristics of pulmonary artery pressure waveform for differential diagnosis of chronic pulmonary thromboembolism and primary pulmonary hypertension. J Am Coll Cardiol 1997; 29: 1311-1316.
9. Ozkan M, Dweik RA, Laskowski D, Arroliga AC, Erzurum SC. High levels of nitric oxide in individuals with pulmonary hypertension receiving epoprostenol therapy. Lung 2001; 179: 233-243.
10. Barst RJ. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin. Heart 1997; 77: 299-301.
11. Castelain V, Chemla D, Humbert M, Sitbon O, Simonneau G, Lecarpentier Y, et al. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med 2002; 165: 338-340.
12. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.
13. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-329.
14. Olschewski H, Ghofrani HA, Walmrath D, Temmesfeld-Wollbruck B, Grimminger F, Seeger W. Recovery from circulatory shock in severe primary pulmonary hypertension (PPH) with aerosolization of iloprost. Intensive Care Med 1998; 24: 631-634.
15. Cohen H, Chahine C, Hui A, Mukherji R. Bosentan therapy for pulmonary arterial hypertension. Am J Health Syst Pharm 2004; 61: 1107-1119.
16. Hill NS, Warburton RR, Pietras L, Klinger JR. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol 1997; 83: 1209-1215.
17. Williamson DJ, Wallman LL, Jones R, Keogh AM, Scroope F, Penny R, et al. Hemodynamic effects of bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation 2000; 102: 411-418.
18. Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, Gomez-Sanchez MA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004; 43: 68S-72S.
19. Kitamukai O, Sakuma M, Takahashi T, Nawata J, Ikeda J, Shirato K. Hemodynamics effect of inhaled nitric oxide using pulse delivery and continuous delivery systems in pulmonay hypertension. Intern Med 2002; 41: 429-434.
20. Perez-Penate G, Julia-Serda G, Pulido-Duque JM, Gorriz-Gomez E, Cabrera-Navarro P. One-year continuous inhaled nitric oxide for primary pulmonary hypertension. Chest 2001; 119: 970-973.
21. Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J. Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension. Chest 2004; 125: 580-586.
22. Bailey CL, Channick RN, Rubin LJ. A new era in the treatment of primary pulmonary hypertension. Heart 2001; 85: 251-252.
23. Ono F, Nagaya N, Kyotani S, Ota H, Nakanishi N, Miyatake K. Hemodynamic and hormonal effects of beraprost sodium, an orally active prostacyclin analogue, in patients with secondary precapillary pulmonary hypertension. Circ J 2003; 67: 375-378.
24. Stiebellehner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R, et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003; 123: 1293-1295.
25. Petkov V, Ziesche R, Mosgoeller W, Schenk P, Vonbank K, Stiebellehner L, et al. Aerosolised iloprost improves pulmonary haemodynamics in patients with primary pulmonary hypertension receiving continuous epoprostenol treatment. Thorax 2001; 56: 734-746.
26. Hoeper MM, Olschewski H, Ghofrani HA, Wilkens H, Winkler J, Borst MM, et al. A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension. German PPH study group. J Am Coll Cardiol 2000; 35: 176-182.
27. Wilkens H, Guth H, König J, Forestier J, Cremers B, Hennen B, et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 2001; 104: 1218-1222.
28. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A, et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42: 158-164.
29. Hoshikawa Y, Voelkel NF, Gesell TL, Moore MD, Morris KG, Alger LA, et al. Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling. Am J Respir Crit Care Med 2001; 164: 314-318.
30. Ziesche R, Petkov V, Wittmann K, Kopatschka J, Stiebellehner L, Schenk P, et al. Treatment with epoprostenol reverts nitric oxide non-responsiveness in patients with primary pulmonary hypertension. Heart 2000; 83: 406-409.